{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:57:57Z","timestamp":1781063877141,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004096","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2005,1,24]],"date-time":"2005-01-24T00:00:00Z","timestamp":1106524800000}}],"reference-count":263,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004096.pub2","type":"journal-article","created":{"date-parts":[[2005,1,17]],"date-time":"2005-01-17T07:17:07Z","timestamp":1105946227000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus"],"prefix":"10.1002","author":[{"given":"Susan L","family":"Norris","sequence":"first","affiliation":[{"name":"Oregon Health Sciences University; Department of Medical Informatics and Clinical Epidemiology; 3181 SW Sam Jackson Park Road Mail Stop B1CC Portland Oregon USA 97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Disease Control and Prevention; Division of Diabetes Translation; 4770 Buford Highway Mail Stop K-10, Davidson Building Atlanta Georgia USA 30341"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Avenell","sequence":"additional","affiliation":[{"name":"University of Aberdeen; Health Services Research Unit; Foresterhill Aberdeen UK AB25 2ZD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gregg","sequence":"additional","affiliation":[{"name":"Center for Disease Control and Prevention; Division of Diabetes Translation; 4770 Buford Highway Mail Stop K-10, Davidson Building Atlanta Georgia USA 30341"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H","family":"Schmid","sequence":"additional","affiliation":[{"name":"Tufts Medical Center; Institute for Clinical Research and Health Policy Studies; 800 Washington St Boston USA MA 02111"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lau","sequence":"additional","affiliation":[{"name":"Tufts Medical Centre; New England Medical Centre\/Tufts Evidence-based Practice Center Institute for Clinical Research and Health Policy Studies; 800 Washington Street Box 63 Boston MA USA 02111"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,24]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD004096.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001857870403900114","article-title":"Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects","volume":"39","author":"Allie","year":"2004","journal-title":"Hospital Pharmacy"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/j.1550-8528.1999.tb00419.x","article-title":"Absence of cardiac valve dysfunction in obese patients treated with sibutramine","volume":"7","author":"Bach","year":"1999","journal-title":"Obesity Research"},{"issue":"6","key":"10.1002\/14651858.CD004096.pub2-BIB0003|cit3","first-page":"816","article-title":"Double-blind clinical evaluation of mazindol (42-548) in obese diabetics","volume":"18","author":"Bandisode","year":"1975","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"11","key":"10.1002\/14651858.CD004096.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1097\/00004872-200311000-00026","article-title":"Orlistat in hypertensive overweight\/obese patients: Results of a randomized clinical trial","author":"Bloch","journal-title":"Journal of Hypertension"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0005|cit5","first-page":"1692","article-title":"Effect of orlistat on glycemic control and body weight in overweight or obese South African patients with type 2 diabetes","volume":"51","author":"Bonnici","year":"2002","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0006|cit6","first-page":"172","article-title":"The efficacy and safety of Mazindol in patients with diabetes mellitus","author":"Boshell","year":"1974","journal-title":"The First International Congress Association for the Study of Obesity"},{"issue":"13","key":"10.1002\/14651858.CD004096.pub2-BIB0007|cit7","first-page":"455","article-title":"Weight reduction in obese diabetics: a double-blind study of diethylpropionate","volume":"91","author":"Bratusch-Marrain","year":"1979","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0008|cit8","first-page":"363","article-title":"Weight control in obese diabetics. A comparetive trial of Filon and Phenmetrazine","volume":"20","author":"Buckle","year":"1966","journal-title":"British Journal of Clinical Practice"},{"issue":"1308","key":"10.1002\/14651858.CD004096.pub2-BIB0009|cit9","first-page":"851","article-title":"A controlled trial of phentermine in obese diabetic patients","volume":"218","author":"Campbell","year":"1977","journal-title":"Practitioner"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0010|cit10","first-page":"A154","article-title":"Fluoxetine has potential in obese NIDDM - Multicenter Canadian trial","volume":"38","author":"Chiasson","year":"1989","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1464-5491.1995.tb00505.x","article-title":"A study of fluoxetine in obese elderly patients with type 2 diabetes","volume":"12","author":"Connolly","year":"1995","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0012|cit12","first-page":"20","article-title":"Noramphetamine, anorectic medication for obese diabetic patients: controlled and open investigations of mazindol","volume":"81","author":"Crommelin","year":"1974","journal-title":"Clinical Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1002\/j.1550-8528.1996.tb00247.x","article-title":"Usefulness of fluoxitine in obese non-insulin-dependent diabetics: a multicenter study","volume":"4","author":"Daubresse","year":"1996","journal-title":"Obesity Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0014|cit14","first-page":"A433","article-title":"Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes","volume":"50","author":"Deerchanawong","year":"2001","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0015|cit15","first-page":"S116","article-title":"Effect of orlistat on insulin resistance, cardiovascular risk factors and serum leptin levels in obese type 2 diabetic patients","author":"Dimitrov","year":"2001","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0016|cit16","first-page":"798","article-title":"Mazindol in the treatment of obese diabetic patients","volume":"22","author":"Dolecek","year":"1976","journal-title":"Vnitrni Lekarstvi"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0017|cit17","first-page":"1214","article-title":"Mazindol in the treatment of obesity in diabetics","volume":"116","author":"Felt","year":"1976","journal-title":"Casopis Lekaru Ceskych"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","article-title":"Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes; a randomised, double-blind, placebo-controlled study","volume":"2","author":"Finer","year":"2000","journal-title":"Diabetes, Obesity Metabolism"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glcaemic control and other metabolic parameters in ovese patients with type 2 diabetes mellitus","volume":"2","author":"Fujioka","year":"2000","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0020|cit20","first-page":"21","article-title":"The effect of a low calorie diet and an anorectic agent on body weight and on serum insulin, cholesterol, and triglyceride levels obese diabetics","volume":"21","author":"Gershberg","year":"1972","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0021|cit21","first-page":"814","article-title":"Effects of diet and an anorectic drug (phentermine resin) in obese diabetics","volume":"22","author":"Gershberg","year":"1977","journal-title":"Current Therapeutic Research"},{"issue":"11","key":"10.1002\/14651858.CD004096.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2337\/diacare.24.11.1957","article-title":"Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control","volume":"24","author":"Gokcel","year":"2001","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD004096.pub2-BIB0023|cit23","first-page":"A767","article-title":"Fluoxetine treatment of obese patients with noninsulin dependent diabetes-mellitus","volume":"39","author":"Goldstein","year":"1991","journal-title":"Clinical Research"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0024|cit24","first-page":"A240","article-title":"Fluoxetine in obese patients with noninsulin-dependent diabetes mellitus","volume":"40","author":"Goldstein","year":"1992","journal-title":"Clinical Research"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0025|cit25","first-page":"200","article-title":"Fluoxetine therapy in obese patients with noninsulin-dependent diabetes mellitus","volume":"57","author":"Goldstein","year":"1995","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0026|cit26","first-page":"167","article-title":"A randomized double-blind clinical trial of fluoxetine in obese diabetics","volume":"16","author":"Gray","year":"1992","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0027|cit27","first-page":"193","article-title":"Fluoxetine treatment of the obese diabetic","volume":"16","author":"Gray","year":"1992","journal-title":"International Journal of Obesity"},{"issue":"Suppl2","key":"10.1002\/14651858.CD004096.pub2-BIB0028|cit28","first-page":"S41","article-title":"Sibutramine in the treatment of overweight non-insulin-dependent diabetics","volume":"19","author":"Griffiths","year":"1995","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0029|cit29","first-page":"144","article-title":"Body composition changes following weight loss induced by sibutramine","volume":"19 (suppl 2)","author":"Griffiths","year":"1995","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0030|cit30","article-title":"Differential weight loss in orlistat treated obese and overweight patients with various comorbidities","volume":"S93","author":"Guy-Grand","year":"2001","journal-title":"International Journal of Obesity"},{"issue":"A436","key":"10.1002\/14651858.CD004096.pub2-BIB0031|cit31","article-title":"Improvement of metabolic control in obese type 2 diabetic patients treated with orlistat for 6 months","volume":"50 (Suppl 2)","author":"Guy-Grand","year":"2001","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0032|cit32","first-page":"A471","article-title":"Modelisation of the 10-year incidence reduction of coronary events in obese Type 2 diabetes patients treated with Orlistat","volume":"51","author":"Guy-Grand","year":"2002","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0034|cit33","first-page":"A437","article-title":"Latin-American multicentric study with orlistat in overweight or obese patients with type 2 diabetes","volume":"50(Suppl 2)","author":"Halpern","year":"2001","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0033|cit34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1463-1326.2003.00262.x","article-title":"Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients","volume":"5","author":"Halpern","year":"2003","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0035|cit35","first-page":"A231","article-title":"Orlistat promotes weight loss and improves glycaemic control in overweight patients with type 2 diabetes","volume":"44","author":"Hanefeld","year":"2001","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1463-1326.2002.00237.x","article-title":"The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"4","author":"Hanefeld","year":"2002","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0037|cit37","first-page":"171","article-title":"Orlistat promotes glucemia control and other cardiovascular risk factors lowering in obese patients with type 2 diabetes. Randomised clinical trial","volume":"43","author":"Hawkins","year":"2000","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0038|cit38","first-page":"337","article-title":"Use of diethylpropion in obese diabetic persons","volume":"11","author":"Hendon","year":"1962","journal-title":"Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0041|cit39","first-page":"566","article-title":"Orlistat enhances weight loss in obese patients with diabetes","volume":"56","author":"Hollander","year":"1997","journal-title":"American Family Physician"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0039|cit40","first-page":"1356","article-title":"Orlistat reduces body weight and cardiovascular disease risk factors in obese men and women with type 2 diabetes","volume":"48","author":"Hollander","year":"1999","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0040|cit41","first-page":"492","article-title":"Orlistat (xenical (R)) reduces cardiovascular disease risk factors in obese patients with type 2 diabetes","volume":"41","author":"Hollander","year":"1998","journal-title":"Diabetologia"},{"issue":"8","key":"10.1002\/14651858.CD004096.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0043|cit43","first-page":"S92","article-title":"Effects of orlistat in obese metformin-treated patients with type 2 diabetes: attainment of treatment goals","volume":"25","author":"Hollander","year":"2001","journal-title":"International Journal of Obesity"},{"issue":"4","key":"10.1002\/14651858.CD004096.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.ijo.0802591","article-title":"Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes","volume":"28","author":"Kaukua","year":"2004","journal-title":"International Journal of Obesity"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0045|cit45","first-page":"21S","article-title":"A one-year study of weight loss and glycemic control in type 2 diabetics following orlistat treatment","volume":"5","author":"Kelley","year":"1997","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0046|cit46","first-page":"A107","article-title":"Effect of orlistat in overweight patients with diabetes receiving insulin therapy","volume":"50(Suppl 2)","author":"Bray","year":"2001","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0048|cit47","first-page":"A439","article-title":"Impact of orlistat on fasting hyperglycemia in obese patients with type 2 diabetes mellitus","volume":"50","author":"Kelley","year":"2001","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0047|cit48","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD004096.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2337\/diacare.27.1.33","article-title":"Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes","volume":"27","author":"Kelley","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0050|cit50","first-page":"48","article-title":"Eight weeks fluoxitine therapy in obese patients with impaired glucose tolerance","volume":"14","author":"Kutnowski","year":"1990","journal-title":"International Journal of Obersity"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0051|cit51","first-page":"S6","article-title":"Fluoxetine therapy in obese diabetic and glucose intolerant patients","volume":"16","author":"Kutnowski","year":"1992","journal-title":"International Journal of Obesity"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0052|cit52","first-page":"S83","article-title":"Biochemical markers of patients with type 2 diabetes and orlistat induced weight loss","volume":"25","author":"Roux","year":"2001","journal-title":"International Journal of Obesity"},{"issue":"3","key":"10.1002\/14651858.CD004096.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study","volume":"248","author":"Lindgarde","year":"2000","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0054|cit54","first-page":"S113","article-title":"Weight loss in type 2 diabetics treatd with orlistat","volume":"25","author":"Martin","year":"2001","journal-title":"International Journal of Obesity"},{"issue":"1","key":"10.1002\/14651858.CD004096.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","journal-title":"Diabetes Care"},{"issue":"(Suppl 1)","key":"10.1002\/14651858.CD004096.pub2-BIB0056|cit56","first-page":"S167","article-title":"Orlistat reduces visceral fat independent of weight changes in obese diabetics type 2","volume":"24","author":"Mendoza-Guadarrama","year":"2000","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"MIles","year":"2002","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0058|cit58","first-page":"A442","article-title":"Effect of orlistat in overweight and obese type 2 diabetes patients treated with metformin","volume":"50","author":"Miles","year":"2001","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0059|cit59","first-page":"2800","article-title":"Experience on the therapeutic use of an anorexic substance in obese diabetes","volume":"55","author":"Montenero","year":"1964","journal-title":"Minerva Medica"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1464-5491.1994.tb00238.x","article-title":"Fluoxetine in the treatment of obese type 2 diabetic patients","volume":"11","author":"O'Kane","year":"1994","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0061|cit61","first-page":"880P","article-title":"The effect of sibutramine on weight loss and glucose metabolism in obese patients with type 2 diabetes mellitus","volume":"48","author":"Peirce","year":"1999","journal-title":"British Journal of Clincial Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD004096.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2337\/diacare.26.9.2505","article-title":"One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes - A radomized trial","volume":"26","author":"Redmon","year":"2003","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0063|cit63","first-page":"93S","article-title":"Weight loss with sibutramine in obese patients with type 2 diabetes: a double-blind, placebo-controlled study","volume":"7","author":"Rissanen","year":"1999","journal-title":"Obesity Research"},{"issue":"15","key":"10.1002\/14651858.CD004096.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"576","DOI":"10.5694\/j.1326-5377.1976.tb130393.x","article-title":"The effect of an anorectic agent (Mazindol) on control of obese diabetics","volume":"2","author":"Sanders","year":"1976","journal-title":"Medical Journal of Australia"},{"issue":"18","key":"10.1002\/14651858.CD004096.pub2-BIB0065|cit65","first-page":"4078","article-title":"Impact of orlistat-induced weight loss on cardiovascular risk estimate in diabetic and non-diabetic subjects","volume":"102","author":"Segal","year":"2000","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0066|cit66","first-page":"A131","article-title":"Orlistat efficacy on weight loss in overweight or obese patients with type 2 diabetes mellitus","volume":"50","author":"Serrano-Rios","year":"2001","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1464-5491.2002.00655.x","article-title":"Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy","volume":"19","author":"Serrano-Rios","year":"2002","journal-title":"Diabetic Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004096.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ajcn\/19.3.158","article-title":"Obesity in diabetes. Some considerations on treatment","volume":"19","author":"Silverstone","year":"1966","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0069|cit69","first-page":"885","article-title":"Clinical evaluation of sibutramine in obese type 2 diabetic patients refractory to dietary management","volume":"49","author":"Sircar","year":"2001","journal-title":"Journal of Association Physicians India"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0070|cit70","first-page":"193","article-title":"Double-blind clinical trial of mazindol on weight loss, blood glucose, plasma insulin and serum lipids in overweight diabetic patients","volume":"4","author":"Slama","year":"1978","journal-title":"Diabetes and metabolism"},{"issue":"11","key":"10.1002\/14651858.CD004096.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.ijo.0800721","article-title":"Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes","volume":"22","author":"Stoa-Birketvedt","year":"1998","journal-title":"International Journal of Obesity"},{"issue":"4","key":"10.1002\/14651858.CD004096.pub2-BIB0072|cit72","first-page":"257","article-title":"Sibutramine in the treatment of obesity in type 2 diabetic patients. [Bulgarian]","volume":"8","author":"Tankova","year":"2003","journal-title":"Endocrinologia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0073|cit73","first-page":"A108","article-title":"Effect of orlistat on cardiovascular risk factors and insulin sensitivity in young obese Chinese type 2 diabetic patients","volume":"50","author":"Chan","year":"2001","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0074|cit74","first-page":"A130","article-title":"The effect of orlistat on body composition in obese diabetic and non-diabetic chinese adults","volume":"50","author":"Sea","year":"2001","journal-title":"Diabetes"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0075|cit75","first-page":"A609","article-title":"A pilot study to examine the efficacy of orlistat and lifestyle modification in Chinese obese subjects with or without Type 2 diabetes mellitus","volume":"51","author":"Sea","year":"2002","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/archinte.162.21.2428","article-title":"The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes","volume":"162","author":"Tong","year":"2002","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0077|cit77","first-page":"188","article-title":"Effects of Sibutramine","volume":"55","author":"Vargas","year":"1994","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0078|cit78","first-page":"46","article-title":"Orlistat in obese type 2 diabetes mellitus: metabolic effects of a short term treatment","volume":"Suppl","author":"Versari","year":"2000","journal-title":"Journal of Endocrinological Investigation"},{"issue":"11","key":"10.1002\/14651858.CD004096.pub2-BIB0079|cit79","first-page":"651","article-title":"Orlistat for adjutant treatment of fatty type 2 diabetes mellitus in 32 patients","volume":"22","author":"Wang","year":"2003","journal-title":"Chinese Journal of New Drugs"},{"issue":"197","key":"10.1002\/14651858.CD004096.pub2-BIB0080|cit80","first-page":"411","article-title":"Trial of a long-acting preparation of diethylpropion in obese diabetics","volume":"200","author":"Williams","year":"1968","journal-title":"Practitioner"},{"issue":"7","key":"10.1002\/14651858.CD004096.pub2-BIB0081|cit81","first-page":"A557","article-title":"Fluoxetine, efficacy and safety in treatment of obese type-2 (non-insulin-dependent) diabetes","volume":"32","author":"Wise","year":"1989","journal-title":"Diabetologia"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0082|cit82","first-page":"S153","article-title":"Highly educative programme added upon treatment with orlistat in type 2 diabetic patients","volume":"26","author":"Zaletel","year":"2002","journal-title":"International Journal of Obesity"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0083|cit83","first-page":"131","article-title":"Growth hormone secretion in obese patients with non-insulin dependent diabetes mellitus: effect of weight reduction and of fluoxetine treatment","volume":"5","author":"Zelissen","year":"1992","journal-title":"Diabetes, Nutrition, and Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD004096.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1001\/archinte.1997.00440320180027","article-title":"Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity","volume":"157","author":"Anchors","year":"1997","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","article-title":"Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine","volume":"106","author":"Apfelbaum","year":"1999","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/ajcn\/42.1.83","article-title":"Enhanced thermogenic responsiveness during chronic ephedrine treatment in man","volume":"42","author":"Astrup","year":"1985","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0087|cit87","first-page":"269","article-title":"The effect and safety of an ephedrine\/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy-restricted diet: A double blind trial","volume":"16","author":"Astrup","year":"1992","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0088|cit88","first-page":"49","article-title":"Reductil (sibutramine hydrochloride) effect in treating obese patients","volume":"7","author":"Boneva","year":"2002","journal-title":"Endocrinologia"},{"issue":"1","key":"10.1002\/14651858.CD004096.pub2-BIB0089|cit89","first-page":"118","article-title":"Addition of orlistat to long term phentermine treatment for obesity","volume":"8","author":"Bowen","year":"2000","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/j.1550-8528.1996.tb00544.x","article-title":"A double-blind randomized placebo-controlled trial of sibutramine","volume":"4","author":"Bray","year":"1996","journal-title":"Obesity Research"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obesity Research"},{"issue":"12","key":"10.1002\/14651858.CD004096.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/0026-0495(95)90077-2","article-title":"Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity","volume":"44","author":"Breum","year":"1995","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0093|cit93","first-page":"S106","article-title":"Randomised trial of the effect of orlistat on body weight and CVD risk profile in overweight and obese patients with co-morbidities","volume":"25","author":"Broom","year":"2001","journal-title":"International Journal of Obesity"},{"issue":"3","key":"10.1002\/14651858.CD004096.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0924-9338(01)00562-4","article-title":"Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series","volume":"16","author":"Chengappa","year":"2001","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0095|cit95","first-page":"104","article-title":"Evaluation of Sanorex-a new appetitie suppressant","volume":"2","author":"Conte","year":"1973","journal-title":"Journal of Obese Bariatric Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0096|cit96","first-page":"S73","article-title":"Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity","volume":"17","author":"Daly","year":"1993","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ajcn\/54.2.321","article-title":"Fluoxetine's effect on weight loss in obese subjects","volume":"54","author":"Darga","year":"1991","journal-title":"American Journal of Clinical Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD004096.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with Orlistat: a randomized controlled trial","volume":"281","author":"Davison","year":"1999","journal-title":"Journal of the American Medical Association"},{"issue":"5","key":"10.1002\/14651858.CD004096.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2125.1999.00928.x","article-title":"Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke","volume":"47","author":"Derby","year":"1999","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0100|cit100","first-page":"221","article-title":"Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study","volume":"19","author":"Drent","year":"1995","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(60)92249-2","article-title":"Phenmetrazine hydrochloride and methylcellulose in the treatment of 'refractory' obesity","volume":"1","author":"Duncan","year":"1960","journal-title":"Lancet"},{"issue":"Mar. 12","key":"10.1002\/14651858.CD004096.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0140-6736(83)92809-X","article-title":"Ephedrine: new treatment for diabetic neuropathic edema","volume":"1","author":"Edmonds","year":"1983","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0103|cit103","first-page":"16","article-title":"Use of teronak for the treatment of obesity with and without diabetes mellitus","volume":"26","author":"Egart","year":"1979","journal-title":"Problemy Endokrinologii"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/030006057600400504","article-title":"Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity","volume":"4","author":"Enzi","year":"1976","journal-title":"The Journal of International Medical Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.ijo.0801098","article-title":"A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity","volume":"24","author":"Fanghanel","year":"2000","journal-title":"International Journal of Obesity"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0106|cit106","first-page":"S115","article-title":"Sibutramine reduces glucose intolerance in centrally obese hypertensive patients","volume":"25","author":"Faria","year":"2001","journal-title":"International Journal of Obesity"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0107|cit107","first-page":"S74","article-title":"Fluoxetine versus sertraline and paroxetine in major depression: long-term changes in weight","volume":"45","author":"Fava","year":"1999","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000177857","article-title":"Comparison of fluoxetine and placebo in the treatment of obesity","volume":"39","author":"Fernandez-Soto","year":"1995","journal-title":"Annals of Nutrition and Metabolism"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"International Journal of Obesity"},{"issue":"3","key":"10.1002\/14651858.CD004096.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/001857870103600311","article-title":"Cimetidine: Weight loss","volume":"36","author":"Generali","year":"2001","journal-title":"Hospital Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF03343971","article-title":"Effects of sibutramine in non-dieting obese women","volume":"25","author":"Gokcel","year":"2002","journal-title":"Journal of Endocrinological Investigation"},{"issue":"1","key":"10.1002\/14651858.CD004096.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1463-1326.2002.00181.x","article-title":"Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity","volume":"4","author":"Gokcel","year":"2002","journal-title":"Diabetes Obesity and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/j.1550-8528.1993.tb00597.x","article-title":"Fluoxitine: a randomized clinical trial in the maintenance of weight loss","volume":"1","author":"Goldstein","year":"1993","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0114|cit114","first-page":"129","article-title":"Fluoxetine: a randomized clinical trial in the treatment of obesity","volume":"18","author":"Goldstein","year":"1994","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/j.1550-8528.1999.tb00420.x","article-title":"Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity","volume":"7","author":"Greenway","year":"1999","journal-title":"Obesity Research"},{"issue":"11","key":"10.1002\/14651858.CD004096.pub2-BIB0116|cit116","first-page":"563","article-title":"Weight reduction with phenmetrazine and chlorphentermine a double-blind study","volume":"9","author":"Hadler","year":"1967","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"25","key":"10.1002\/14651858.CD004096.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJM200012213432502","article-title":"Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids","volume":"343","author":"Haller","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0118|cit118","first-page":"404","article-title":"Effect of orlistat on post-prandial glucose levels in overweight or obese patients with type 2 diabetes","volume":"51","author":"Hanefeld","year":"2002","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/j.1550-8528.1998.tb00351.x","article-title":"A comparison of sibutramine and dexfenfluramine in the treatment of obesity","volume":"6","author":"Hanotin","year":"1998","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.ijo.0801481","article-title":"Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity, results from the European multi-centre STORM trial","volume":"25","author":"Hansen","year":"2001","journal-title":"International Journal of Obesity"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1093\/ajcn\/55.1.309s","article-title":"Initial studies in humans with the novel gastointestinal lipase inhibitor Ro 18-0647","volume":"55","author":"Hauptman","year":"1992","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","article-title":"Orlistat in the long-term treatment of obesity in primary care settings","volume":"9","author":"Hauptman","year":"2000","journal-title":"Archives of Family Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjp.0702067","article-title":"A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents","volume":"125","author":"Heal","year":"1998","journal-title":"British Journal of Pharmacology"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0124|cit124","first-page":"1346","article-title":"Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus","volume":"48","author":"Heath","year":"1999","journal-title":"Diabetes"},{"issue":"9","key":"10.1002\/14651858.CD004096.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","article-title":"Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults","volume":"160","author":"Heymsfield","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/ajcn\/69.6.1108","article-title":"Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study","volume":"69","author":"Hill","year":"1999","journal-title":"American Journal of Clinical Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD004096.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1464-5491.1987.tb00887.x","article-title":"Treatment of patients with non-insulin-dependent diabetes mellitus: diabetic control and insulin secretion and action after different treatment modalities","volume":"4","author":"Hollenbeck","year":"1987","journal-title":"Diabetic Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/ajcn\/55.1.199s","article-title":"Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan","volume":"55","author":"Inoue","year":"1992","journal-title":"American Journal of Clinical Nutrition"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1002\/j.1550-8528.1995.tb00226.x","article-title":"Clinical studies with mazindol","volume":"3","author":"Inoue","year":"1995","journal-title":"Obesity Research"},{"issue":"6","key":"10.1002\/14651858.CD004096.pub2-BIB0130|cit130","first-page":"1693","article-title":"Effect of Orlistat on glycemic control in patients on or near maximal doses of oral anti-diabetic (OAD) medications","volume":"51","author":"Jacob","year":"2002","journal-title":"Diabetes"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0131|cit131","first-page":"S24","article-title":"A one year trial to assess the value of orlistat in the management of obesity","volume":"21","author":"James","year":"1997","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial","volume":"256","author":"James","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0133|cit133","first-page":"41","article-title":"Long term weight loss with sibutramine","volume":"19","author":"Jones","year":"1995","journal-title":"International Journal of Obesity"},{"issue":"4","key":"10.1002\/14651858.CD004096.pub2-BIB0134|cit134","first-page":"289","article-title":"A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity","volume":"16","author":"Langlois","year":"1974","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0135|cit135","first-page":"A307","article-title":"Therapeutic comparison of metformin and fluoxetine alone and in combination in obese subjects with impaired glucose tolerance","volume":"48","author":"Lee","year":"1999","journal-title":"Diabetes"},{"issue":"4 part 1","key":"10.1002\/14651858.CD004096.pub2-BIB0136|cit136","first-page":"A268","article-title":"Use of metformin and fluoxetine combination in obese subjects with glucose intolerance","volume":"13","author":"Lee","year":"1999","journal-title":"The FASEB Journal"},{"issue":"5","key":"10.1002\/14651858.CD004096.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2337\/diacare.23.5.618","article-title":"Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial","volume":"23","author":"Lustman","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0138|cit138","first-page":"1122","article-title":"Cost-effectiveness of treatment of overweight and obese diabetic patients with Orlistat","volume":"51","author":"Maetzel","year":"2002","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.ijo.0800372","article-title":"Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss","volume":"21","author":"Maheux","year":"1997","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0140|cit140","first-page":"183","article-title":"Ephedrine as an anorectic: The story of the \"Elsinore pill\"","volume":"5","author":"Malchow-Moller","year":"1981","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/ajp.147.7.876","article-title":"A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters","volume":"147","author":"Marcus","year":"1990","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD004096.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/meta.2001.24220","article-title":"Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity","volume":"50","author":"McLaughlin","year":"2001","journal-title":"Metabolism, Clinical and Experimental"},{"issue":"14","key":"10.1002\/14651858.CD004096.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension - A 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004096.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF01930467","article-title":"Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics","volume":"48","author":"Meier","year":"1992","journal-title":"Experientia"},{"issue":"8","key":"10.1002\/14651858.CD004096.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1176\/ajp.156.8.1170","article-title":"Changes in weight during a 1-year trial of fluoxetine","volume":"156","author":"Michelson","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0146|cit146","first-page":"A442","article-title":"Effect of orlistat in overweight and obese type 2 diabetes patients treated with metformin","volume":"50","author":"Miles","year":"2001","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0147|cit147","first-page":"A475","article-title":"Effect of orlistat on the need for concomitant anti-diabetic medication in overweight and obese patients with type 2 diabetes","volume":"51","author":"Miles","year":"2002","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0148|cit148","first-page":"163","article-title":"Does ephedrine promote weight loss in low-energy-adapted obese women?","volume":"11","author":"Pasquali","year":"1987","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/j.1550-8528.1996.tb00268.x","article-title":"The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial","volume":"4","author":"Pedrinola","year":"1996","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/bmj.306.6885.1093","article-title":"Cimetidine suspension as adjuvant to energy restricted diet in treating obesity","volume":"306","author":"Rasmussen","year":"1993","journal-title":"British Medical Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0152|cit152","first-page":"S93","article-title":"Weight loss with sibutramine in obese patients with type 2 diabetes: a double-blind, placebo-controlled study","volume":"7","author":"Rissanen","year":"1999","journal-title":"Obesity Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0153|cit153","first-page":"A270","article-title":"Sibutramine-induced weight loss improves lipid profile in obese type 2 diabetics: Results of 3 placebo-controlled, randomized trials","volume":"49","author":"Rissanen","year":"2000","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0154|cit154","first-page":"657","article-title":"Weight loss on sibutramine treatment for 12 months improves lipid profile in obese type 2 diabetic patients","volume":"443","author":"Rissanen","year":"2000","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.1550-8528.1998.tb00308.x","article-title":"Sibutramine reduces food intake in non-dieting women with obesity","volume":"6","author":"Rolls","year":"1998","journal-title":"Obesity Research"},{"issue":"1","key":"10.1002\/14651858.CD004096.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1463-1326.2002.00161.x","article-title":"Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects","volume":"4","author":"Rosenfalck","year":"2002","journal-title":"Diabetes Obesity and Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD004096.pub2-BIB0157|cit157","first-page":"875","article-title":"Effect of moderate weight loss on health-related quality of life: An analysis of combined data from 4 randomized trials of sibutramine vs placebo","volume":"7","author":"Samsa","year":"2001","journal-title":"American Journal of Managed Care"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0158|cit158","first-page":"561","article-title":"Yohimbine does not affect fat distribution in men","volume":"15","author":"Sax","year":"1991","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/j.1550-8528.1998.tb00324.x","article-title":"Effects of sibutramine on resting metabolic rate and weight loss in overweight women","volume":"6","author":"Seagle","year":"1998","journal-title":"Obesity Research"},{"issue":"5","key":"10.1002\/14651858.CD004096.pub2-BIB0160|cit160","first-page":"398","article-title":"Diethylpropion hydrochloride (Tenuate Dospan) in combination with hypotensive agents in the treatment of obesity associated with hypertension","volume":"16","author":"Seedat","year":"1974","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004096.pub2-BIB0161|cit161","first-page":"A101","article-title":"Effect of orlistat on weight loss and glycemic control in overeight Chinese patients with type 2 diabetes","volume":"50","author":"Shi","year":"2001","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00000441-197106000-00005","article-title":"Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine","volume":"261","author":"Sirtori","year":"1971","journal-title":"The American Journal of Medical Science"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trail of orlistat for weight losss and prevention of weight regain in obese patients; European Multicentre Orlistat Study Group","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0164|cit164","first-page":"232","article-title":"A comparative trial of different regimens of fenfluramine and phentermine in obesity","volume":"211","author":"Steel","year":"1973","journal-title":"Practitioner"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bmj.306.6885.1091","article-title":"Effect of cimetidine suspension on appetite and weight in overweight subjects","volume":"306","author":"Stoa-Birketvedt","year":"1993","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1464-5491.2002.00823.x","article-title":"Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus","volume":"19","author":"Tan","year":"2002","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2337\/diacare.21.6.987","article-title":"Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin","volume":"21","author":"Thompson","year":"1998","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD004096.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/diacare.22.7.1137","article-title":"Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients","volume":"22","author":"Toft-Nielsen","year":"1999","journal-title":"Diabetes Care"},{"issue":"4-5","key":"10.1002\/14651858.CD004096.pub2-BIB0169|cit169","first-page":"142","article-title":"The reduction of overweight and the improvement of metabolic parameters with the lipase inhibitor orlistat: Preliminary results [German]","volume":"25","author":"Toplak","year":"1998","journal-title":"Acta Medica Austriaca"},{"issue":"5","key":"10.1002\/14651858.CD004096.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0197-2456(01)00165-9","article-title":"Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience","volume":"22","author":"Torgerson","year":"2001","journal-title":"Controlled Clinical Trials"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004096.pub2-BIB0171|cit171","first-page":"S73","article-title":"The acute and chronic effects of ephedrine\/caffeine mixtures on energy expenditure and glucose metabolism in humans","volume":"17","author":"Toubro","year":"1993","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002280050433","article-title":"Efficacy and tolerability of orlistat in the treatment of obesity - A 6-month dose-ranging study","volume":"54","author":"Gaal","year":"1998","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004096.pub2-BIB0173|cit173","first-page":"S272","article-title":"Sibutramine trial of obesity reduction and maintenance. Effects on risk factors","volume":"22","author":"Gaal","year":"1998","journal-title":"International Journal of Obesity"},{"issue":"Suppl","key":"10.1002\/14651858.CD004096.pub2-BIB0174|cit174","first-page":"S55","article-title":"Fluoxetine increases insulin action in obese type-II (non-insulin-dependent) diabetic-patients","volume":"16","author":"Vanloon","year":"1992","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0175|cit175","first-page":"124","article-title":"Controlled comparative investigation of mazindol, D-amphetamine, and placebo","volume":"3","author":"Vernace","year":"1974","journal-title":"Obesity\/Bariatric Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/j.1550-8528.1995.tb00189.x","article-title":"Sertraline and relapse prevention training following treatment by very-low-calorie diet: A controlled clinical trial","volume":"3","author":"Wadden","year":"1995","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/j.1550-8528.1997.tb00296.x","article-title":"Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach","volume":"5","author":"Wadden","year":"1997","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archinte.161.2.218","article-title":"Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial","volume":"161","author":"Wadden","year":"2001","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/030006057700500202","article-title":"A multicentre atudy comparing mazindol and placebo in obese patients","volume":"5","author":"Walker","year":"1977","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/diacare.23.7.1039","article-title":"Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients","volume":"23","author":"Wasada","year":"2000","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0181|cit181","first-page":"A126","article-title":"Obesity with orlistat (Xenical) helps to prevent deterioration in glucose tolerance","volume":"41","author":"Wilding","year":"1998","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0182|cit182","first-page":"A215","article-title":"Orlistat-induced weight loss improves insulin resistance in obese patients","volume":"42","author":"Wilding","year":"1999","journal-title":"Diabetologia"},{"issue":"Suppll 2","key":"10.1002\/14651858.CD004096.pub2-BIB0183|cit183","first-page":"S108","article-title":"Early response to orlistat treatment predicts long-term success in overweight and obese patients with co-morbidities","volume":"25","author":"Wilding","year":"2001","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0184|cit184","first-page":"231","article-title":"Weight reduction in osteoarthritis using phentermine","volume":"225","author":"Williams","year":"1981","journal-title":"Practitioner"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0185|cit185","first-page":"86","article-title":"A clinical evaluation of Tenuate- a new anti-appetite compound","volume":"46","author":"Wilson","year":"1960","journal-title":"Journal of Irish Medical Association"},{"issue":"11","key":"10.1002\/14651858.CD004096.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight losss with sibutramine: a randomized, controlled trial","volume":"286","author":"Wirth","year":"2001","journal-title":"Journal of American Medical Association"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0187|cit187","first-page":"546","article-title":"A double-blind controlled trial of a new anorectic agent AN448","volume":"81","author":"Woodhouse","year":"1975","journal-title":"The New Zealand Medical Journal"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0188|cit188","first-page":"125","article-title":"Usefulness of mazinol in combined diet therapy consisting of low-calorie diet and optifast in severely obese women","volume":"104","author":"Yoshida","year":"1994","journal-title":"International Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00004872-199816121-00024","article-title":"Treatment with orlistat reduces cardiovascular risk in obese patients","volume":"16","author":"Zavoral","year":"1998","journal-title":"Journal of Hypertension"},{"issue":"27","key":"10.1002\/14651858.CD004096.pub2-BIB0190|cit190","first-page":"1247","article-title":"Therapy of obesity with \"Redukal\"","volume":"26","author":"Ziegler","year":"1971","journal-title":"Das Deutsche Gesundheitswesen"},{"issue":"suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.2337\/diacare.26.2007.S33","article-title":"Standards of medical care for patients with diabetes mellitus","volume":"26","author":"American Diabetes Association","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetic Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0193|cit193","first-page":"931","article-title":"Publication bias in obesity treatment trials?","volume":"20","author":"Allison","year":"1996","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials; a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielson","year":"2003","journal-title":"Journal of the American Medical Association"},{"issue":"suppl 4","key":"10.1002\/14651858.CD004096.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"326S","DOI":"10.1038\/oby.2001.138","article-title":"Obesity and disease management: effects of weight loss on comorbid conditions","volume":"9","author":"Anderson","year":"2001","journal-title":"Obesity Research"},{"issue":"9072","key":"10.1002\/14651858.CD004096.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(05)62352-5","article-title":"Does blinding of readers affect the results of meta-analyses? Results of a randomized trial","volume":"350","author":"Berlin","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"55G","DOI":"10.1016\/0002-9149(87)90592-3","article-title":"Medical evaluation of the obese patient with cardiovascular disease","volume":"60","author":"Blackburn","year":"1987","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/edrv.20.6.0383","article-title":"Current and potential drugs for treatment of obesity","volume":"20","author":"Bray","year":"1999","journal-title":"Endocrinology Reviews"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/diacare.19.6.613","article-title":"Promoting weight loss in type II diabetes","volume":"19","author":"Brown","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0005-7894(87)80004-7","article-title":"Improving long-term weight loss: pushing the limits of treatment","volume":"18","author":"Brownell","year":"1987","journal-title":"Behavioral Therapy"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0201|cit201","unstructured":"Clarke M Oxman AD Cochrane Reviewers' Handbook 4.2.0 (updated March 2003) Oxford The Cochrane Library 2003"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archpsyc.1981.01780320043003","article-title":"Behavior therapy and pharmacotherapy for obesity","volume":"38","author":"Craighead","year":"1981","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/diab.28.12.1039","article-title":"Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance","volume":"28","author":"National Diabetes Data Group","year":"1979","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004096.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1954","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.285.15.2000","article-title":"Physican interpretations and textbook definitions of blinding terminology in randomized controlled trials","volume":"285","author":"Devereaux","year":"2002","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/bmj.325.7360.381","article-title":"Systematic reviews and lifelong diseases","volume":"325","author":"Elphick","year":"2002","journal-title":"British Medical Journal"},{"issue":"suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diacare.25.2007.S5","article-title":"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","volume":"25","author":"The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.288.14.1723","article-title":"Prevalence and trends in obesity among U.S. adults, 1999-2000","volume":"288","author":"Flegal","year":"2002","journal-title":"Journal of American Medical Association"},{"issue":"5","key":"10.1002\/14651858.CD004096.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcn\/60.5.647","article-title":"Long-term weight loss: the effect of pharmacologic agents","volume":"60","author":"Goldstein","year":"1994","journal-title":"American Journal of Clinical Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD004096.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/152091599317198","article-title":"Obesity medications and the treatment of type 2 diabetes","volume":"1","author":"Greenway","year":"1999","journal-title":"Diabetes Technology & Therapeutics"},{"issue":"suppl 7","key":"10.1002\/14651858.CD004096.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/sj.ijo.0800956","article-title":"The impact of pharmacotherapy on weight management in type 2 diabetes","volume":"23","author":"Hauner","year":"1999","journal-title":"International Journal of Obesity & Related Metabolic Disorders"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0215|cit215","unstructured":"Health Canada Advisory: Health Canada investigates safety of MERIDIA (sibutramine). Health Canada Online 3-27-2002"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archinte.1997.00440270105009","article-title":"Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure","volume":"157","author":"The Trials of Hypertension Prevention Collaborative Research Group","year":"1997","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7326\/0003-4819-120-8-199404150-00008","article-title":"Guidelines for meta-analyses evaluating diagnostic tests","volume":"120","author":"Irwig","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0218|cit218","article-title":"Assessment the quality of RCTs: why, what, how, and by whom?","volume-title":"Randomised Controlled Trials","author":"Jadad","year":"1998"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0306-4603(87)90044-X","article-title":"Selective attrition causes overestimates of treatment effects in studies of weight loss","volume":"12","author":"Kaplan","year":"1987","journal-title":"Addictive Behavior"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diacare.21.9.1414","article-title":"Global Burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections","volume":"21","author":"King","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0221|cit221","first-page":"123","article-title":"Long-term follow-up of behavioral treatment for obesity: patterns of weight regain in men and women","volume":"13","author":"Kramer","year":"1989","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/bmj.308.6925.367","article-title":"By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?","volume":"308","author":"Law","year":"1994","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/ajcn\/69.3.373","article-title":"Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men","volume":"69","author":"Lee","year":"1999","journal-title":"American Journal of Clinical Nutrition"},{"issue":"11","key":"10.1002\/14651858.CD004096.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.2337\/diacare.20.11.1744","article-title":"The prevention and treatment of obesity. Application to type 2 diabetes","volume":"20","author":"Maggio","year":"1997","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1002\/14651858.CD004096.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2337\/diacare.23.9.1278","article-title":"Diabetes trends in the U.S.: 1990-1998","volume":"23","author":"Mokdad","year":"2000","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1002\/14651858.CD004096.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jama.286.10.1195","article-title":"The continuing epidemics of obesity and diabetes in the United States","volume":"286","author":"Mokad","year":"2001","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1001\/jama.1996.03540230057036","article-title":"Long-term pharmacotherapy in the management of obesity","volume":"276","author":"National Task Force on the Prevention and Treatment of Obesity","year":"1996","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0228|cit228","volume-title":"Clinical guidelines on the identification, evaluation, and treatment of overwieght and obesity in adults: the evidence report","author":"National Heart","year":"1998"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0229|cit229","first-page":"1073","article-title":"Health implications of obesity: National Institutes of Health Consensus Development Conference Statement","volume":"1034","author":"National Institutes of Health","year":"1985","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-277X.1998.00098.x","article-title":"Systematic review of the effectiveness of interventions used in the management of obesity","volume":"11","author":"O'Meara","year":"1998","journal-title":"Journal of Human Nutrition and Dietetics"},{"issue":"Issue 4","key":"10.1002\/14651858.CD004096.pub2-BIB0231|cit231","article-title":"Long-term pharmacotherapy for obesity and overweight Long-term pharmacotherapy for obesity and overweight","author":"R","year":"2004","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD004096.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/oby.2002.77","article-title":"Combining behavioral and pharmacological treatments for obesity","volume":"10","author":"Phelan","year":"2002","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00006","article-title":"Medical hazards of obesity","volume":"119","author":"Pi-Sunyer","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2337\/diacare.23.10.1451","article-title":"Weight loss and mortality in type 2 diabetes","volume":"23","author":"Pi-Sunyer","year":"2000","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD004096.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/(SICI)1520-7560(200003\/04)16:2<114::AID-DMRR97>3.0.CO;2-O","article-title":"Antiobesity pharmacotherapy in the management of type 2 diabetes","volume":"16","author":"Scheen","year":"2000","journal-title":"Diabetes and Metabolism Research Reviews"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0236|cit236","first-page":"437","article-title":"New antiobesity agents in type 2 diabetes: Overview of clinical trials with sibutramine and orlistat","volume":"28","author":"Scheen","year":"2002","journal-title":"Diabetes & Metabolism (Paris)"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/9780470693926.ch11","article-title":"Investigating and dealing with publication and other biases","volume-title":"Systematic Reviews in Health Care; Meta-analysis in Context","author":"Sterne","year":"2001"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0895-4356(99)00204-8","article-title":"Misleading funnel plot for detection of bias in meta-analysis","volume":"53","author":"Tang","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"suppl 1","key":"10.1002\/14651858.CD004096.pub2-BIB0239|cit239","first-page":"1","article-title":"Introducing the Guide to Community Preventive Services: methods, first recommendations and expert commentary","volume":"18","author":"Task Force on Community Preventive Services","year":"2000","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"Thornton","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0242|cit242","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine and dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations","volume":"46","author":"U. S. Department of Health and Human Services","year":"1997","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0243|cit243","unstructured":"U. S. Department of Health and Human Services CDC Atlanta GA National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2000 2002 \/\/www.cdc.gov\/diabetes\/pubs\/factsheet.htm (Accessed Oct. 2, 2003)"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0244|cit244","unstructured":"U.S. Department of Health and Human Services Diabetes: disabling, deadly and on the rise, 2002 At-A-Glance Atlanta, GA National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0246|cit246","first-page":"490","article-title":"Effects of weight loss on morbidity and mortality","volume-title":"Eating Disorders and Obesity","author":"Valdez","year":"2002"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0247|cit247","first-page":"39","article-title":"Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective","volume":"13","author":"Wadden","year":"1989","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0025-7125(05)70230-3","article-title":"Behavioral treatment of obesity","volume":"85","author":"WaddenTA","year":"2000","journal-title":"Medical Clinics of North America"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archinte.161.2.218","article-title":"Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial","volume":"161","author":"Wadden","year":"2001","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0250|cit250","article-title":"The global strategy on diet, physical activity and health","author":"World Health Organization","journal-title":"http:\/\/www.who.int\/hpr\/NPH\/docs\/gs_global_strategy_general.pdf"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0251|cit251","article-title":"Obesity and overweight","author":"World Health Organization","journal-title":"http:\/\/www.who.int\/hpr\/NPH\/docs\/gs_obesity.pdf"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0252|cit252","first-page":"1","article-title":"World Health Organization Technical Report","volume-title":"World Health Organization Technical Report Series","volume":"646","author":"WHO Expert Committee on Diabetes Mellitus","year":"1980"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0253|cit253","article-title":"World Health Organization Technical Report.","volume-title":"World Health Organization Technical Report Series 727","volume":"727","author":"WHO Expert Committee on Diabetes Mellitus","year":"1985"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2337\/diacare.23.10.1499","article-title":"Intentional weight loss and mortality among overweight individuals with diabetes","volume":"23","author":"Williamson","year":"2000","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD004096.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1037\/0022-006X.53.1.111","article-title":"Behavior change, weight loss, and physiological improvements in type II diabetic patients","volume":"53","author":"Wing","year":"1985","journal-title":"Journal of Consulting and Clinical Psychology"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/archinte.1987.00370100063012","article-title":"Long-term effects of modest weight loss in type II diabetic patients","volume":"147","author":"Wing","year":"1987","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/archinte.1991.00400070100012","article-title":"Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects","volume":"151","author":"Wing","year":"1991","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.1093\/ajcn\/55.2.545s","article-title":"Behavioral treatment of severe obesity","volume":"55","author":"Wing","year":"1992","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0259|cit259","first-page":"252","article-title":"Weight loss in the management of type 2 diabetes","volume-title":"Evidence-Based Diabetes Care","author":"Wing","year":"2000"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0260|cit260","first-page":"650","article-title":"Strategies for changing eating and exercise behavior","volume-title":"Present knoweldge in nutrition","author":"Wing","year":"2001"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0261|cit261","unstructured":"Wolfe S Sasich LD Barbehenn E Letter from Public Citizen to Tommy Thompson, Secretary DHHS Public Citizen Website"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMra012586","article-title":"Obesity","volume":"346","author":"Yanovski","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004096.pub2-BIB0263|cit263","unstructured":"The University of York Centre for Reviews and Dissemination The prevention and treatment of obesity Effective Health Care Bulletin London The Royal Society of Medicine Press Ltd"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004096.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T12:51:55Z","timestamp":1705755115000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004096.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2005,1,24]]},"references-count":263,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004096.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,24]]}}}